Expertise in
3
conditions

Dr. Janet C. Dubois

Dermatology
Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, 
Austin, TX 
Accepting New Patients
Referral may be required
Before you request
Expertise in
3
conditions
Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, 
Austin, TX 

Overview

Janet Dubois is a Dermatologist practicing medicine in Austin, Texas.

Dr. Dubois is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Seborrheic Keratosis, Actinic Keratosis, Rosacea, and Acne.

She is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 10 clinical trials. Dr. Dubois is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, Austin, TX 78759

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Enrollment Status: Withdrawn
Publish Date: November 07, 2017
Intervention Type: Drug, Device
Study Phase: Phase 3
View 9 Less Clinical Trials

30 Total Publications

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral required
Before you request

Vitalogy Skincare CP

1464 E Whitestone Blvd Ste 301, 
Cedar Park, TX 
 (7.9 miles away)
512-260-3376
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tricia Winters is a Dermatologist practicing medicine in Cedar Park, Texas. Dr. Winters is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Keratitis-Ichthyosis-Deafness Syndrome, Netherton Syndrome, Ichthyosis Bullosa of Siemens, and Peeling Skin Syndrome. Dr. Winters is currently accepting new patients.

Expertise in
56
conditions
Expertise in
56
conditions
Referral may be required

Austin Diagnostic Clinic - Westlake

1250 S Capital Of Texas Hwy Bldg 3, 
West Lake Hills, TX 
 (9.2 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Stacia Miles is a Dermatologist practicing medicine in West Lake Hills, Texas. Dr. Miles is highly rated in 56 conditions, according to our data. Her clinical expertise encompasses Pustules, Syringocystadenoma Papilliferum, Syringoma, and Sebaceous Adenoma. Dr. Miles is currently accepting new patients.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required
Before you request

Office

1610 E Whitestone Blvd, 
Cedar Park, TX 
 (9.0 miles away)
512-260-3376
Languages Spoken:
English, Greek, Spanish
See accepted insurances
Accepting New Patients

Christopher Jones is a Dermatologist practicing medicine in Cedar Park, Texas. Dr. Jones is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Universal Acquired Melanosis, Liver Spots, Actinic Keratosis, and Warts. Dr. Jones is currently accepting new patients.

Frequently Asked Questions about Dr. Janet C. Dubois

How do I make an appointment with Dr. Janet C. Dubois?

You can book an appointment with Dr. Janet C. Dubois by calling their office at 512-345-3599. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Janet C. Dubois a top-rated expert for Seborrheic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Janet C. Dubois is classified as an Advanced expert for Seborrheic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Janet C. Dubois specialize in?

While Dr. Janet C. Dubois is a Dermatology, they have specific expertise in Seborrheic Keratosis, Actinic Keratosis, and Rosacea. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Janet C. Dubois participate in research or clinical trials?

Yes. Dr. Janet C. Dubois has published 30 articles and abstracts on conditions like Seborrheic Keratosis. You can view a list of Dr. Janet C. Dubois's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Janet C. Dubois accept my insurance?

Dr. Janet C. Dubois accepts most major insurance plans, including Aetna and UnitedHealthcare. We recommend calling the office directly at 512-345-3599 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dubois's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile